Combination of transcatheter arterial chemoembolization and anti-PD-L1
liposomes therapy suppressed hepatocellular carcinoma progression in
mice
Abstract
Background To study the effects of combination TACE and anti-PD-L1
liposome drug in treating HCC in mice models. Methods We constructed the
liposome drug with lecithin and cholesterol and mannitol, etc. Besides,
the HCC mice model was established through abdominal subcutaneous
injection HepG2 cancer cells in SD mice, then the PE-10 polyethylene
catheter was used for TACE therapy. The SD mice were separately received
TACE treatment, avelumab liposome drug therapy, and TACE combined with
avelumab liposome drug therapy. Results The liposomes drug was
successfully constructed with a diameter of 125.5 nm. After the mice
received TACE and (or) immunotherapy, the combined liposome drug therapy
significantly reduced the volume of hepatic carcinoma tissues, besides,
the apoptotic rates of hepatic carcinoma cells in the combined liposome
drug treatment group was increased obiviously compared with other
groups. Moreover, the protein TGFβR2 located in the cellular membrane
was obiviously down-regulated in the combined liposome drug therapy,
whilst, the expression of SMAD7 and PTPN14 was up-regulated in the
treatment groups compared with the mice without treatment, besides, the
protein PTPN14 was mainly located in the nucleus. Additionally, the mRNA
expression of genes SNAI1 and Vimentin was significantly down-regulated
in the combined liposome drug therapy. Conclusion Combination of
transcatheter arterial chemoembolization and anti-PD-L1 liposome drug
therapy significantly suppressed hepatocellular carcinoma proliferation
and metastasis in mice models.